Radiopharm Theranostics Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Radiopharm Theranostics Limited, a foreign private issuer, covers the month of December 2025. The report was filed on December 19, 2025, and serves to disclose three announcements published to the Australian Securities Exchange regarding changes in directors' interests.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of corporate governance events rather than a financial performance statement.
Material Changes
The material change disclosed is the alteration of shareholdings or interests held by three directors, identified by the initials IT, PH, and RC. No financial or operational changes were reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document explicitly states it is not deemed "filed" for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings.
Key Facts for Investor Verification
- Verify the specific nature and magnitude of the interest changes for directors IT, PH, and RC in the attached exhibits (99.1, 99.2, 99.3).
- Confirm the current total shareholding of the directors following these changes.
- Note that this filing does not contain financial results; refer to the most recent Form 20-F for financial data.